Led by researchers from Ohio State University, the study focuses on the mutations in the spike protein of BA.2.86, specifically finding that it “appears to have increased infectivity of human lung epithelial cells compared to all omicron variants…(which) raises a potential concern about whether or not this virus is more pathogenic,” Shan-Lu Liu, MD, PhD, senior author the study and a virology professor at OSU stated in a news release.
And while still effective, they also concluded that bivalent vaccine efficiency is also reduced for this variant.
The CDC would not directly comment on the findings on severity of these two COVID-19 strains since it was an outside study, but did point to its most recent report, which highlights that JN.1 is an offspring of BA.2.86, according to the CDC, and currently accounts for 62% of all COVID-19 cases nationally.
As infections and hospitalizations have sharply increased for multiple weeks in a row, the CDC report also notes that the recent strain, JN.1, “may be intensifying the spread of COVID-19 this winter.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
